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Transgenic mice expressing the full-length HCV coding sequence were crossed with mice that express the HBV X gene-encoded regulatory
protein HBx (ATX mice) to test the hypothesis that HBx expression accelerates HCV-induced liver pathogenesis. At 16 months (mo) of age,
hepatocellular carcinoma was identified in 21% of HCV/ATX mice, but in none of the single transgenic animals. Analysis of 8-mo animals
revealed that, relative to HCV/WT mice, HCV/ATX mice had more severe steatosis, greater liver-to-body weight ratios, and a significant increase
in the percentage of hepatocytes staining for proliferating cell nuclear antigen. Furthermore, primary hepatocytes from HCV, ATX, and HCV/ATX
transgenic mice were more resistant to fas-mediated apoptosis than hepatocytes from nontransgenic littermates. These results indicate that HBx
expression contributes to increased liver pathogenesis in HCV transgenic mice by a mechanism that involves an imbalance in hepatocyte death
and regeneration within the context of severe steatosis.
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Worldwide, chronic infection with hepatitis C virus (HCV)
and hepatitis B virus (HBV) affects 170 million and 300 million
people, respectively. Both viruses target the liver and chronic
infection with either is a significant risk factor for the
development of hepatocellular carcinoma (HCC) (Beasley,
1988; Di Bisceglie et al., 1994; Saito et al., 1990; Slagle et al.,
1994). With more than 400,000 annual deaths worldwide, liver
cancer is considered a major cause of cancer mortality (Parkin et
al., 1999). Additional independent risk factors for the
development of HCC include chemical agents such as ethanol
and hepatocarcinogens (Chen et al., 1997; Wogan, 1992; Yu et⁎ Corresponding author. Fax: +1 713 798 5075.
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doi:10.1016/j.virol.2005.11.050al., 2000). There is evidence in transgenic mice for the
cooperation between these risk factors. For example, transgenic
mice expressing the HBV surface antigen or regulatory HBx
protein showed a greater than 2-fold increase in the incidence of
carcinogen-induced liver nodules and HCC compared to treated
nontransgenic littermate controls (Dandri et al., 1996; Madden
et al., 2001; Sell et al., 1991; Slagle et al., 1996).
There is epidemiological evidence that chronic coinfection
with HBVand HCVmay lead to a more severe prognosis. While
some studies failed to demonstrate such a synergism (Donato et
al., 1997), other studies clearly demonstrate a greater than
additive risk of HCC in patients coinfected with HBVand HCV
(Kew et al., 1997; Tsai et al., 1996). A meta-analysis of 32
studies involving a total of 4560 cases of HCC and 6988
controls revealed that the odds ratio (OR) of HCC for people
coinfected with HBV and HCV (OR = 135; 95% confidence
Fig. 1. Transgene expression. (A) Schematic representation of HCV and ATX
transgenes. The HCV FL-N/35 transgene encodes the full-length HCV
polyprotein driven by the murine albumin promoter, as described (Lerat et al.,
2002). The ATX transgene encodes the entire HBV X (adw2) open reading
frame under control of the human α-1-antitrypsin promoter, as described
previously (Lee et al., 1990). (B) Representative IP/Western blot detection of
HBx in livers from 8-mo mice. Portions of liver tissue from each animal in this
study were analyzed for the presence of HBx, as described in Materials and
methods. The arrows at the right note the migration of IgG and HBx; molecular
weight markers are shown at the left. The asterisk marks the migration of a
nonspecific band detected in all lanes. Genotypes of mice include Lane 1, WT/
WT; Lane 2, WT/ATX; Lane 3, HCV/WT; Lane 4, HCV/ATX. (C) Antibody
detection of HCV NS3 and HBx in formalin-fixed liver tissue. Viral proteins
expressed from the transgenes were detected using rabbit polyclonal antiserum
as described in Materials and methods. Controls include the omission of the
primary antibody (top row) (400×). Specificity of the staining reaction is
revealed by the lack of staining for NS3 in ATX livers or of HBx in HCV livers.
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chronic infection with either HBV (OR = 20.4; 95% confidence
18.0–23.2) or HCV (OR = 23.6; 95% confidence 20.0–28.1)
(Donato et al., 1998). There is a need for the development of
experimental models to confirm such synergy between these
viruses in order to probe the underlying mechanism(s) of
pathogenesis.
The role of HCV proteins in carcinogenesis has been studied
in transgenic mice expressing individual viral proteins or the
entire HCV genome under control of a liver-specific promoter
(reviewed in Liang and Heller, 2004). Transgenic mice that
express either a high abundance of the HCV core protein or a
much lower abundance of the full-length HCV polyprotein (FL-
N/35 mice) have been shown to accumulate intrahepatic fat
(steatosis), and older male mice from these lineages are at risk
for developing HCC (Lerat et al., 2002; Moriya et al., 1998). We
have characterized transgenic mice that express the HBV
regulatory HBx protein throughout their lifespan (ATX mice)
(Lee et al., 1990) and at levels similar to that measured for the
woodchuck X protein (WHx) in chronically-infected wood-
chucks (Dandri et al., 1998; Madden et al., 2001). While HBx
expression in the ATX mice is not associated with liver
pathology (Lee et al., 1990; Madden et al., 2000), a tumor
promoter role for HBx has been established in vivo in the
presence of a liver carcinogen (Madden et al., 2001; Slagle et al.,
1996; Zhu et al., 2004). This cofactor role for HBx has also been
demonstrated for transgenic mice that express the woodchuck
WHx protein (Dandri et al., 1996).
As HCV and HBV appear to act synergistically in the
development of human HCC, we sought to establish an animal
model that would permit the investigation of this interaction.
The purpose of the present study was to test the hypothesis that
the HBx protein will accelerate liver pathology in the FL-N/35
HCVmice. The FL-N/35 mice were crossed with ATXmice and
the F1 male progeny sacrificed at 16 mo to allow for the
development of liver tumors, and at 8 mo to permit observance
of preneoplastic changes. By 16 months of age, HCCs
developed only in mice harboring both the HCV and ATX
transgenes, and analysis of livers and primary hepatocyte
cultures revealed an imbalance in hepatocyte death and
regeneration.
Results
Generation of double transgenic mice
Previous studies have established a low incidence of HCC in
transgenic mice harboring the HCV core gene (Lerat et al.,
2002; Moriya et al., 1998) or the full-length HCV transgene
(Lerat et al., 2002; Moriya et al., 1998). Our previous studies of
ATX mice have not identified any pathology associated with
HBx expression (Lee et al., 1990; Madden et al., 2000), unless
liver carcinogens are present (Madden et al., 2001, 2002; Slagle
et al., 1996). In the present study, we hypothesized that HBx
would accelerate HCC formation in the HCV mice. To test this
hypothesis, heterozygous female ATX mice were crossed with
heterozygous male HCV mice (Fig. 1A), and F1 male progenyused. Mice were genotyped as described in Materials and
methods, and expression of HBx was confirmed for all HCV/
ATX mice using a combination immunoprecipitation (IP)/
Western blot procedure (Fig. 1B, representative result). The
expression level of HBx in the HCV/ATX double transgenic
mice (Fig. 1B, lane 4) was similar to that observed in an age-
matched ATX littermate (Fig. 1B, lane 2), and is comparable to
that measured during chronic hepadnavirus infection (Dandri et
al., 1996). Expression levels of HBx were similar among HCV/
ATX livers from both the 8- and 16-mo time points (data not
shown). Expression of both transgenes was confirmed in these
livers by Immunohistochemical (IHC) staining for the HCV
NS3 protein and HBx (Fig. 1C). Both NS3 and HBx were found
Fig. 2. Histological changes in livers of HCV/WT and HCV/ATX mice. (A)
Compression of host hepatocytes (at left) by growing tumor tissue (at right)
(100×); (B) Normal liver (left), transitional fatty tissue (center), tumor nodule
(right) (25×); (C) Normal liver, showing few Ki-67 positive cells (i.e., cells
undergoing DNA synthesis), in contrast to a higher frequency of Ki-67 positive
cells in tumor tissue (D) (100×); (E) HCC from HCV/ATX liver, showing
nodular scaring identified by trichrome stain (25×); (F) HCC from HCV/ATX
liver, showing positive (red) reaction for AFP (200×).
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previously described for their localization in liver cells of
infected patients (Errington et al., 1999; Hoare et al., 2001).
Importantly, this is the first demonstration of HCV protein
expression in the FL-N/35 HCV mice.
Increased incidence of HCC in 16-mo HCV/ATX mice
Previous studies have shown a low tumor incidence in the
HCV FL-N/35 mice. Additionally, expression of HBx alone has
no observable effect on liver histology, the frequency of
spontaneous DNA mutations, or the development of spontane-
ous HCC (Lee et al., 1990; Madden et al., 2000). To determine
whether HBx might enhance HCC development in the HCV
mice, we sacrificed animals at 16 mo and examined their livers
for evidence of tumors. Of the 14 HCV/ATX animals sacrificed,
3 (21%) had HCCs, while no tumors were detected in 19 HCV/
WT mice nor in any WT or ATX mice (Table 1). This increased
incidence in HCCs in the HCV/ATX mice, relative to that in
HCV/WT mice, approached statistical significance (P = 0.0667;
Fisher's exact test). All three tumors in the HCV/ATX mice
were large (0.5 to 1.5 cm diameter), and were diagnosed as
HCC based on histological features such as increased nuclear-
to-cytoplasmic ratio, nuclear pleomorphism, increased baso-
philic staining, compression of adjacent normal liver tissue
(Figs. 2A, B, E), atypical architecture (Fig. 2E), increased
cellular proliferation (Figs. 2C, D), and the presence of alpha-
fetoprotein (AFP) (Fig. 2F). While no lung metastases were
noted in the tumor-bearing animals, pulmonary metastasis is
rarely observed in mice less than 24 months of age (Frith and
Wiley, 1982). These results demonstrate that liver tumors
developed only in mice expressing both the HCV and ATX
transgenes.
The absence of tumors in the 19 HCV/WT mice was
surprising, as a previous analysis of HCV FL-N/35 mice
revealed an HCC incidence of 13% in animals 13 to 19 months
of age (Lerat et al., 2002). The most likely explanation for the
absence of HCCs in the HCV mice in our study is that the miceTable 1
Incidence of hepatocellular carcinoma
Genotype a Age at sacrifice
(months)
Mice with HCCb/
total no. in group
(% of group with HCC)
WTc 13–20 0/38
ATXd N16 0/400
HCV/WT 16 0/19
HCV/ATX 16 3/14 (21%)
a Presence of transgene determined by PCR, immunoprecipitation/Western
blot, and IHC staining, as described in Materials and methods.
b Diagnosis of HCC based on nuclear pleomorphism, increased nuclear-to-
cytoplasmic ratio, disruption of tissue architecture, and positive staining for
alpha-fetoprotein (AFP).
c WT, nontransgenic littermates, including 18 mice from breeding generations
F0 to F7 (Lerat et al., 2002) and 20 mice from generation F4 to F8 (unpublished
results).
d ATX, data from mice sacrificed 1990–2004 and as reported (Madden et al.,
2000; Slagle et al., 1996).are now on a C57BL/6 genetic background that is relatively
resistant to HCCs (Akamatsu, 1975; Frith andWiley, 1982). It is
known that the C3H genetic background is susceptible to
spontaneous HCC (Akamatsu, 1975; Flaks, 1968), and the
contribution of the C3H genetic background to the HCVmice in
the earlier study was 6.25 to 25% (Lerat et al., 2002) (Table 2).
In contrast, the HCV mice in the present study contain less than
0.2% of the C3H genetic background and do not show the HCC
phenotype, unless HBx is present. Further support for thisTable 2
Influence of C3H genetic background on tumor incidence observed in FL-N/35
mice
Generation % C3H
background
Age at
sacrifice
(months)
HCV mice with
HCC/total mice
(% of group)
Sex Reference
F0–F3 50–6.25 N13 5/16 (30%) a M Unpublished
F0–F7 50–0.4 N13 5/38 (13%) M, F Lerat et al.
(2002)
F4–F7 3.1–0.4 N13 0/14 b M Unpublished
NF8 0.2 16 0/19 M Present
study
a High incidence of HCC in early generations of HCV FL-N/35 mice is likely
due to a high proportion of C3H genetic background, consistent with other
studies of mice C3H genetic background (Akamatsu, 1975; Flaks, 1968).
b Lack of spontaneous HCCs on predominantly C57BL/6 genetic background
has been reported previously (Frith and Wiley, 1982).
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frequency of HCC in FL-N/35 mice backcrossed into the C3H
genetic background (Urszula Hibner, personal communication).
Analysis of serum samples from fasted 16-mo mice was
consistent with the histology results. Serum from tumor-bearing
mice had dramatically elevated ALT levels (50- to 200-fold)
compared to that measured in nontumor mice (data not shown).
Even when tumor-bearing mice were excluded from the HCV/
ATX group, a significant 2.2-fold increase in ALT levels was
observed in 16-mo HCV/ATX (vs. HCV/WT) mice (P b 0.006),
indicating increased hepatocyte damage even in HCV/ATX
livers that lacked tumors. Rare inflammatory foci were observed
in both genotypes. All other serum test results (outlined in
Materials and methods) were not statistically different between
the HCV/WT vs. HCV/ATX genotypes of mice.
Hepatic steatosis is more severe in HCV/ATX mice
Examination of formalin-fixed, H&E-stained liver tissue
sections revealed the presence of large cytoplasmic vacuoles in
hepatocytes of both single and double transgenic mice (Figs. 3A,
B). These vacuoles stained positive with Oil Red O dye, and
therefore contain neutral lipids (data not shown). This result
confirms the previous demonstration that HCV FL-N/35 mice
develop mild to moderate fat accumulation (steatosis) in
hepatocytes (Lerat et al., 2002). Since it was possible that steatosis
might contribute to pathology in our animal model, we measured
both the frequency and the severity of steatosis in the 8-mo mice.
Random sections from multiple liver lobes were collected atFig. 3. Increased severity of steatosis in double transgenic mice. Formalin-fixed,
H&E-stained liver sections from 8-mo HCV/WT (A) and HCV/ATX (B) mice.
(C) Severity of steatosis, determined as described in Materials and methods.
Data are shown in a boxplot. The line within each box represents the median
scores. The bottom and top lines represent the 25th and 75th percentiles. The
whisker indicates the 90th percentile, and filled circles are mild outliers.
P values were calculated by use of the Mann–Whitney rank sum test.sacrifice, and livers scored for the presence or absence of steatosis
as described in Materials and methods. One hundred percent of the
livers from 8-mo HCV/ATX mice contained cytoplasmic vacuoles
compared to 61% of the 8-mo HCV/WT mice, suggesting that
steatosis develops earlier in the double-transgenic mice. The
severity of steatosis was also scored, as described in Materials and
methods, on the same tissue sections. Quantitatively more severe
steatosis was found in 8-mo HCV/ATX livers than in HCV/WT
littermates (median scores 1.5 vs. 1.0, respectively; P b 0.05 using
the Mann–Whitney rank sum test) (Fig. 3C).
Increased liver-to-body weight ratio in 8-mo HCV/ATX mice
We next examined livers from the 8-mo sacrifice time point
for evidence of preneoplastic changes that might predict the
increased HCC phenotype found in HCV/ATX mice. None of
the livers removed from animals sacrificed at the 8-mo time
point revealed any gross pathology. However, important
differences were noted in the liver-to-body weight ratio. Liver
size is tightly regulated by a balance between cell death and
regeneration, and perturbations in these processes are often a
prerequisite to disease (Michalopoulos and DeFrances, 1997).
The total body weight of the WT, ATX, HCV/WT and HCV/
ATX mice was indistinguishable at 8 months of age (Fig. 4A).
When compared to WT mice, the HCV/WT mice had
significantly decreased liver-to-body weight ratios that were
not observed in the HCV/ATX mice (Fig. 4B). This result
suggests an imbalance in the regulation of liver size in the HCV/
WT mice that is restored to normal in the HCV/ATX mice.
Imbalance in hepatocyte apoptosis and proliferation
It was possible that the decreased liver-to-body weight ratio
observed in 8-mo HCV/WT mice was due to an imbalance in
hepatocyte death and/or regeneration. Primary hepatocyte
cultures were obtained by liver perfusion of WT, ATX, HCV,
and HCV/ATXmice, and were treated with fas-agonist antibody
Jo2 to determine whether there was a differential response to
this apoptotic stimulus. The activation of caspase 3 was
measured by Western blot assays that detect cleaved 17 and
19-kDa caspase 3 proteins. WT mice treated with Jo2 antibody
had the highest levels of activated caspase 3, while the levels
present in ATX, HCV/WT, and HCV/ATX hepatocytes were
significantly reduced (Figs. 5A, B). These data confirm
previous results demonstrating that primary hepatocytes from
HCV/WT FL-N/35 mice (Disson et al., 2004) and from
transgenic mice expressing the HCV structural proteins
(Machida et al., 2001) are protected against fas-mediated
apoptosis. In addition, this is the first report that primary
hepatocytes from ATX mice are protected from fas-mediated
apoptosis, relative to hepatocytes fromWT littermates, although
the protection is at a lower level than observed in the HCV
hepatocytes. Expression of HBx in the HCV/ATX hepatocytes
did confer greater protection to caspase 3 activation stimulated
by the fas pathway; however, this synergistic effect of HBx and
HCV did not reach statistical significance when compared to
hepatocytes from single transgenic mice (Fig. 5B).
Fig. 4. Increased liver-to-body weight ratio in HCV/ATX mice. (A) Body weight of 8-mo mice following an overnight fast. The weight of WT (n = 5), ATX (n = 1),
HCV/WT (n = 23), and HCV/ATX (n = 10) mice is shown. (B) Littermates were sacrificed at 8 months of age following a 16-h fast, and the liver-to-body weight ratio
determined for WT (n = 5), ATX (n = 1), HCV/WT (n = 23), and HCV/ATX (n = 10) mice. In both panels, error bars represent standard error of the mean (SEM). P
values were calculated by use of the Student's t test.
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treatment, using a cell viability test (XTT) on hepatocyte
cultures in microwell plates. Compared to hepatocytes fromWT
mice, those from ATX and HCV/WT mice were significantly
more resistant to Jo2 antibody-induced cell death (Fig. 5C),
with a relative increase in survival rate of 27% ± 14 and
40% ± 6, respectively. In addition, expression of both
transgenes conferred a 73% ± 10 increase of survival, compared
to WT hepatocytes, which was significantly higher than the
survival provided by either transgene alone (Fig. 5C; P b 0.05).
These results demonstrate that in HCV/WT and HCV/ATX
livers there is a deregulation of the fas pathway, a cellular
pathway essential for the homeostasis of the liver.
Since HBx has previously been shown to have a tumor
promoter role in carcinogen-induced liver cancer (Dandri et
al., 1996; Madden et al., 2001; Slagle et al., 1996; Zhu et al.,
2004), we considered that HBx might have a similar role in the
development of HCCs in the HCV/ATX mice. Liver sections
from 8-mo WT, ATX, HCV, and HCV/ATX mice were stained
with antibody against proliferating cell nuclear antigen
(PCNA), a nuclear antigen expressed in cells preparing to
undergo DNA synthesis. The percentage of PCNA-positive
hepatocytes was very low in livers of age-matched WT and
ATX mice, and was not significantly different between the two
genotypes (Fig. 6; P = 0.2). Livers from age-matched HCV/
WT mice revealed a significant increase in PCNA staining,
and this level was increased further in the livers of HCV/ATX
mice (Fig. 6; P b 0.05). This result of increased PCNA
staining in the HCV/WT and HCV/ATX mice is consistent
with the observation of increased PCNA staining in livers with
specific histological diagnoses, including steatosis (Akyol et
al., 1999). Importantly, an effect of HBx on the incidence of
PCNA-positive hepatocytes was apparent only on the HCV
background. Together, the apoptosis and PCNA results
indicate an apparent imbalance between liver cell death and
regeneration in the 8-mo HCV/WT and HCV/ATX animals.
Indeed, the increase in PCNA-positive nuclei detected in the 8-
mo HCV/WT and HCV/ATX livers correlated with the
increase in liver-to-body weight ratio measured in those
animals when tested by a nonlinear regression analysis
(r2 = 0.98; data not shown).The results of this study suggest a model in which reactive
hepatitis and steatosis in HCV/ATX mice, measured by
increased ALT levels, precedes the development of HCC. The
hepatocytes of single and double transgenic mice have a
decreased capacity to recognize fas-mediated signals, relative to
hepatocytes from WT mice, but only the HCV/WT and HCV/
ATX hepatocytes have a significantly increased capacity for cell
proliferation. The effect of HBx on proliferation was not
apparent in age-matched single transgenic ATX mice, which do
not develop steatosis. Importantly, the synergy of HCV with
HBx observed in the present study mirrors what is observed in
humans coinfected with HCV and HBV.
Discussion
Chronic infection with both HBVand HCVappears to lead to
a risk of HCC that is significantly greater than that associated
with infection with either virus alone, suggesting a possible
synergy between these viruses (Donato et al., 1998). In the
present study, we identified HCC in 21% of the 16-mo HCV
transgenic mice that additionally express the HBx protein
compared to no HCC in the HCV/WT littermates. In this model,
the tumors arose on a background of reactive hepatitis and
steatosis, which was more severe in the HCV/ATX animals
compared to that in HCV/WT mice. Together, our results
suggest that HBx may act as a cofactor in HCV-mediated liver
disease. However, the mechanism by which HCV and HBx
interact is unclear.
The absence of HCCs in HCV/WT mice in the present study
was unexpected, as the original description of the FL-N/35 mice
revealed a tumor incidence of 13% (Lemon et al., 2000; Lerat et
al., 2002). We note that the previous studies included HCVmice
in which a large portion of the genetic background was C3H, an
inbred strain known to have a high incidence of spontaneous
liver tumors (Akamatsu, 1975; Flaks, 1968). It is likely that the
phenotype conferred by HCV in the earlier studies was more
easily observed because of the C3H genetic background. In
contrast, the HCV transgene in the present study is expressed on
the C57BL/6 background, an inbred strain that displays a very
low incidence of spontaneous liver tumors (Akamatsu, 1975;
Frith and Wiley, 1982).
Fig. 6. Hepatocyte proliferation associated with HBx expression. Antibody
staining for the detection of PCNAwas performed and quantitated as described
in Materials and methods. Mean PCNA values for 8-mo WT and ATX livers
(which lack steatosis) were compared, as were HCV/WTand HCV/ATX (which
both possess steatosis). Error bars represent SEM, and significance was
determined by the Student's t test.
Fig. 5. Primary hepatocytes from double transgenic mice are protected from fas-
mediated apoptosis. (A) Primary hepatocytes from the different transgenic mice
were isolated, cultivated, and treated with Jo2 as described in Materials and
methods. Activated caspase 3 was detected (see Materials and methods), and an
antibody against GAPDH was used to normalize the amount of protein loaded
on the gel. (B) Graphic display of densitometry results for caspase 3. Bands of
activated caspase 3 were quantified by densitometry and normalized using the
GAPDH expression. Bars represent the average of caspase 3 activation in 3
different mice per lineage, except ATX (n = 1). (C) Cell survival following Jo2
treatment. Primary hepatocytes cultivated in 96-well plates were treated with
0.01 ng/ml Jo2, and their survival assessed 24 h later using XTT test as described
in Material and methods. Cell survival measured from WT hepatocytes treated
with Jo2 was set to zero for each of three experiments, and the increase of cell
survival for ATX (n = 2), HCV (n = 3), and HCV/ATX (n = 3) hepatocytes was
measured relative to that of WT hepatocytes. Error bars represent SEM, and
cyclohexamide (CHX) was included in all experiments.
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incidence in HCV/ATX mice centers on the ability of both HCV
and HBx to alter apoptotic pathways. The HCV FL-N/35 mice
used in the present study were recently shown to be deficient in
fas-mediated apoptosis (Disson et al., 2004), which theoreti-
cally could contribute to the survival of cells that contain DNA
damage. The influence of HBx on apoptotic pathways in the cell
is less clear. In cultured cells, HBx blocks fas-mediated
apoptosis (Diao et al., 2001; Gottlob et al., 1998; Pan et al.,
2001), but can be proapoptotic in the presence of DNAdamaging agents (Bergametti et al., 1999; Chirillo et al., 1997).
In the present study, we demonstrated that primary hepatocytes
from both ATX and HCV mice were deficient in fas-mediated
apoptosis, and that expression of HBx in the HCV/ATX
hepatocytes did confer additional statistically significant
survival against fas-mediated killing beyond that measured for
the hepatocytes from single transgenic mice (Fig. 5C). These
results support the prediction that both the HCV/WT and HCV/
ATX livers may be unable to eliminate cells containing DNA
damage, relative to livers of nontransgenic mice. The survival of
such damaged cells would be predicted to contribute to eventual
tumorigenesis if the additional cooperating events occur.
A second possible mechanism to explain the HCC formation
in the double transgenic mice centers on the steatosis observed
in both HCV/WT and HCV/ATX mice. Evidence is accumu-
lating to suggest that hepatic steatosis is an independent risk
factor for HCC (Bugianesi et al., 2002). Several studies have
additionally concluded that HCV may contribute toward
increasing severity of steatosis (see review Lonardo et al.,
2004), although it is not clear whether the virus acts directly or
indirectly to accomplish this. Transgenic mice that overexpress
the HCV core protein also develop steatosis (Barba et al., 1997;
Moriya et al., 1997), and HCV proteins have been found
associated with cytoplasmic lipid droplets in cultured cells
(Barba et al., 1997). While the HCV mice used in the present
study were not directly tested for expression of the Core protein,
we were able to demonstrate the expression of another HCV
protein (NS3) that is part of the viral polyprotein. This is the first
report of HCV protein detection in the FL-N/35 mice, and
supports the earlier detection of low levels of full-length RNA
transcripts (Lerat et al., 2002). The HCV mice used in this study
also were shown to develop steatosis, particularly in aging
males, as described previously (Lerat et al., 2002). In the present
study, steatosis was both more prevalent and severe in the
presence of HBx expression.
Although it is not certain that steatosis contributes directly to
HCC, it has been proposed that this condition may be associated
472 V.V. Keasler et al. / Virology 347 (2006) 466–475with mitochondrial injury and oxidative stress leading to lipid
peroxidation, the release of proinflammatory cytokines, and
ultimately chromosomal DNA damage (Okuda et al., 2002).
Conditional expression of the HCV core protein also has been
shown to directly induce an abnormal accumulation of reactive
oxygen species in cultured cells, probably on the basis of
mitochondrial injury (Okuda et al., 2002). The mechanism by
which HBx might synergize with the DNA damage component
of steatosis is intriguing to consider. HBx is known to bind to
DNA repair protein DDB1 (Lee et al., 1995; Sitterlin et al.,
1997) and the ability of HBx to inhibit DNA repair (Becker et
al., 1998; Groisman et al., 1999; Jia et al., 1999; Prost et al.,
1998), coupled with the increase in reactive oxygen species
production in HCV mice, might explain the increase in the
incidence of HCC observed in the double transgenic mice.
While HBx has been shown to inhibit the repair of ultraviolet-
damaged DNA, its ability to inhibit the repair of oxidative DNA
damage has not been tested.
It is known that HBx is able to deregulate the cell cycle, both
in cell culture (Benn and Schneider, 1995; Koike et al., 1994;
Lee et al., 2002) and in vivo (Madden and Slagle, 2001;
Madden et al., 2001). We and others have previously shown that
HBx possesses a tumor promoter role in carcinogen-induced
HCC (Dandri et al., 1996; Madden et al., 2001; Slagle et al.,
1996; Zhu et al., 2004). In the present study, HBx expression in
8-mo HCV/ATXmice was associated with a significant increase
in PCNA-positive hepatocytes. However, this effect of HBx
was only observed on a background of HCV-associated
steatosis, and was not apparent in 8-mo ATX livers which
lack steatosis. It is not clear whether this increase in PCNA
represents compensatory regeneration following apoptosis, or a
synergy of HBx expression with cellular factors that are present
in steatotic liver. However, the strong correlation between
PCNA staining and liver-to-body weight ratio, coupled with
protection to fas-mediated apoptosis in both HCV/WT and
HCV/ATX mice, suggests that HBx-driven hepatocyte prolif-
eration could act in concert with reduced apoptosis to promote
the growth of cells containing damage.
A third possible mechanism to explain the increased tumor
incidence in the HCV/ATX double transgenic mice centers on a
possible interaction of the transgenes being expressed. The
virus titers in coinfected patients often show inhibitory
interactions between HBV and HCV. Some studies have
concluded that HBV infection seems to suppress HCV
replication (Francois et al., 1994; Jardi et al., 2001; Kazemi-
Shirazi et al., 2000), while other studies have concluded that
HBV titers are suppressed by coinfection with HCV (Jardi et al.,
2001; Tanaka et al., 2004). Interestingly, HBx is reported to
transactivate many viral and cellular genes (reviewed in
Rossner, 1992), and so might be anticipated to transactivate
expression of the albumin promoter controlling expression of
the HCV transgene. However, HBx failed to transactivate the
albumin promoter when tested in HepG2 cells (Hu et al., 1990;
Rossner et al., 1990). While our Western blot and IHC analysis
of HCV/ATX and HCV/WT livers did not reveal any striking
differences in transgene levels being expressed (Figs. 1B, C),
these types of analyses are not quantitative.Finally, a 2-fold increase in ALT was measured in 16-mo
HCV/ATX mice that lacked tumors, but the significance of
this observation is unclear. Although it is possible that the
ALT levels represent damage due to steatosis, the association
between elevated ALT levels and increasing grade of
steatosis in humans is reported to vary from 50 to 90%
(see review, Sanyal, 2002). Thus, it is likely that the ALT
increases we observed signify increased hepatocyte injury,
but whether this is a direct result of the steatosis or an
indirect consequence of other interactions between the
transgenes remains unknown.
In summary, we have described a novel double-transgenic
mouse model in which the interaction of the full-length HCV
genome and the HBV HBx protein was evaluated. To our
knowledge, this is the first animal model that directly examines
the potential interaction between HCV and HBx. While neither
the HCV/WT or WT mice in the present study nor untreated
ATX mice in any previous report developed spontaneous HCC
by 16 months of age, 21% of HCV/ATX mice developed HCC
in our study. This type of greater-than-additive synergy is
similar to that described for humans that are coinfected with
both HCV and HBV (Donato et al., 1998), and is interpreted to
suggest that the viruses act along a similar pathway in the
development of HCC. With this animal model, it will now be
possible to examine molecular mechanisms of this synergy in a
setting that is biologically relevant.
Materials and methods
Transgenic mice
Approval for all experiments involving animals was obtained
from the Institutional Animal Care and Use Committee at
Baylor College of Medicine. Transgenic mice harboring the X
gene (ATX mice; nucleotides 1234 to 1986 of X subtype adw2)
(Fig. 1A) (Lee et al., 1990) were maintained as heterozygotes by
crossing with wild-type female ICR mice. The HCV mice used
in this study were lineage FL-N/35 and were obtained from
BIOCON, Inc. (Rockville, MD). FL-N/35 mice harbor the
entire HCV polyprotein coding region (nucleotides 342 to 9378,
strain N, genotype 1b) under the control of the liver-specific
albumin promoter (Fig. 1A) (Lerat et al., 2002). The absence of
the 5′ and 3′ untranslated regions (UTRs) of the HCV genome
in the transgene negates any possibility that these mice could
produce infectious HCV particles, and thus eliminates any
potential safety hazard to laboratory workers. The genotypes of
F1 progeny were determined by polymerase chain reaction
(PCR) analysis of mouse tail high molecular weight (HMW)
DNA, using X-specific oligonucleotide primers 5′-ATGGC-
TGCTAGGCTGTACTG-3′ and 5′-GTACAAGAGATGAT-
TAGGCAGA-3′ (Valenzuela et al., 1980) and HCV E2 gene-
specific primers 5′-CAACCCTACGTACAGCTG-3′ and
5′-GGTAGTCAACCATGCACC-3′. Substitution of water for
HMW DNA was included as a negative control in all PCR
reactions. PCR conditions were 94 °C for 0.5 min and 56 °C for
1 min (40 cycles). Products were resolved on a 1% agarose gel.
Mouse genotype was also confirmed by immunoprecipitation
473V.V. Keasler et al. / Virology 347 (2006) 466–475(IP)/Western blot and by immunohistochemistry (IHC), as
described below.
Sacrifice and harvest of mice
Following an overnight fast, mice were anesthetized by
intraperitoneal injection of Rodent Combo III, containing
acepromazine, 80 mg/kg ketamine, and 16 mg/kg xylazine.
Anesthetized mice were weighed and the removed liver
weighed separately for the determination of liver-to-body
weight ratio. Serum samples were collected, and representative
portions of each liver lobe were removed and flash-frozen in
liquid nitrogen. Other portions of the liver were fixed in neutral
buffered formalin overnight for subsequent histology studies.
The serum samples were run through a COBAS INTEGRA 400
plus high throughput analyzer to determine the level of common
liver-specific markers, including total protein, albumin, globulin,
A/G ratio, gamma-glutamyltranspeptidase, alkaline phosphatase,
alanine aminotransferase (ALT), aspartate aminotransferase
(AST), total and indirect bilirubin, cholesterol, lactate dehydroge-
nase, triglycerides, and very low density lipoprotein.
Histological and IHC analyses
Liver tissue fixed overnight (approximately 16 h) in neutral
buffered formalin was transferred to 70% ethanol followed by
paraffin embedding. Sections of 4–5 μm were cut, deparaffi-
nized, and stained with hematoxylin and eosin (H&E), for
histological analysis, and trichrome, for detection of collagen
types I and III. Slides were coded and examined by a pathologist
(MJF). Staining for proliferating cell nuclear antigen (PCNA; a
nuclear protein involved in DNA repair and growth regulation)
was performed as described previously (Madden and Slagle,
2001) using a 1:5000 dilution of mouse monoclonal antibody
PC10 (Santa Cruz Biotechnology). IHC detection of HBx
protein was performed using rabbit antibody prepared against
HBx subtype adw2, as described (Henkler et al., 1995).
Detection of HCV nonstructural 3 (NS3) protein was performed
as described (Errington et al., 1999) using rabbit antiserum
prepared against HCV NS3 protein (genotype 1). Staining for
AFP was performed using mouse anti-AFP (Zymed) at
1:12,000. Staining for the DNA synthesis marker Ki-67 was
performed as described (Gerdes et al., 1991) using a 1:500
dilution of mouse monoclonal antibody M7240 (Dako,
Carpenteria, CA) following antigen retrieval with citrate buffer
for 25 min at 100 °C. Bound antibody was detected using the
MultiLink kit from BioGenex (San Ramon, CA). Frozen tissue
sections were stained with Oil Red O dye to identify neutral
lipids.
Primary hepatocyte cultures
Hepatocytes were isolated from the transgenic and control
mice by portal vein perfusion of collagenase (Disson et al.,
2004). Freshly isolated hepatocytes were cultivated in 6- and
96-well plates in Dulbeco's Minimal Essential Medium
(GibcoBRL) supplemented with 10% heat inactivated fetalcalf serum, 0.5 μmol/L dexamethasone, 10 μg/ml insulin, 5.5
μg/ml human transferrin (iron-free), and 5 ng/ml sodium
selenite. Cells were plated overnight at 37 °C and in 5% CO2,
then washed and used for further experiments within 3 days of
plating.
Cell viability assay
Primary cells were seeded at 1.8 × 104 cells per well in 96
well plates (Microtest Primeria flat bottom, Falcon). Apoptosis
was induced the next day using a fas-agonist antibody Jo2
(PharMingen, San Diego, CA) at 0.01 ng/ml in the presence of 5
μg/ml of CHX. Cell viability was assessed using the XTT
colorimetric test (Roche Diagnostic) according to the manufac-
turer's instructions. XTT reagent was incubated 2 h and ODs
were read at 450 nm (with a reference at 630nm) using a Wallac
Victor2 1420 multilabel counter from PerkinElmer.
Apoptosis assays
Primary hepatocytes were treated with Jo2 antibody in the
presence of CHX (5 μg/ml). Cells were harvested 22 to 24
h later, washed twice in phosphate buffered saline containing 10
mM EDTA, and proteins extracted using the PARIS kit
(Ambion). Protein concentration from the primary hepatocyte
extracts was assessed using the BCA assay (Pierce Biotechnol-
ogy, Inc. Rockford, IL) and 30 to 40 μg of protein was analyzed
by 15% SDS polyacrylamide electrophoresis. Separated
proteins were transferred to nitrocellulose and incubated with
an antibody against activated caspase 3 (New England Biolabs).
Detection of the caspase 3 activated large fragments (17 and 19
kDa) was performed using enhanced chemiluminescence
(Pierce Biotechnology, Inc.), and antibody to GAPDH (Novus
Biologicals, Littleton, CO) was used to normalize protein
loading.
Immunoprecipitation and Western blot detection of HBx
Liver extracts were prepared as described (Madden et al.,
2000). Subsequent immunoprecipitation and Western blot
analysis were used to verify expression of HBx and were
performed using 2 mg of total liver protein and rabbit polyclonal
anti-HBx serum, as described (Madden et al., 2000). Bound
antibody was detected using an avidin–biotin detection kit
(Vector Laboratories), and enhanced chemiluminescence
(Amersham Biosciences, Piscataway, NJ).
Quantitation and statistical analysis
Two different individuals separately scored histologic
findings quantitatively using coded tissue sections. Quantita-
tion of PCNA-positive hepatocytes (e.g., cells in late G1 or S
phase) was accomplished by counting positive nuclei in 10
random high power fields (each containing approximately 600
hepatocytes) from livers of at least 5 representative animals of
each genotype. The mean percentage of PCNA-positive
hepatocytes (of the total cells counted) was compared. The
474 V.V. Keasler et al. / Virology 347 (2006) 466–475incidence of hepatocellular steatosis was evaluated by scoring
each liver tissue section for the presence or absence of any
cytoplasmic vacuoles. The severity of hepatic steatosis was
determined by the method of Brunt et al. (1999). Briefly,
coded H&E-stained liver tissue sections from each animal in
the study were scored for the percentage of hepatocytes in
each lobule that contained cytoplasmic vacuoles, with scores
given as ‘0’ (no vacuolization), ‘1’ (up to 33% of cells
involved), ‘2’ (33 to 66% of cells), or ‘3’ (greater than 66%
of cells). The code was then broken, and the mean score
value compared between genotypes, and significance deter-
mined using the Mann–Whitney rank sum test. The liver-to-
body weight ratio was determined for each animal in the
study, and the mean value compared between genotypes at
each sacrifice time point. The Student's t test (Microsoft
Excel software package) was utilized to calculate statistical
significance of the liver-to-body weight ratios, activated
caspase 3 expression, and cell survival assays. The Fisher's
exact test was used to determine significance among
genotypes of mice for the proportion of mice with tumors.
Nonlinear regression analysis was used to determine a
correlation between PCNA staining and liver-to-body weight
ratio, in which an r2 value of 0.8 to 1.0 is considered a strong
correlation. Error bars are reported as standard error of the
mean, and significance was assigned for a score of P b 0.05
for the Student's t test, the Fisher's exact test, and the Mann–
Whitney rank sum test.Acknowledgments
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